Scarica l'app Stockscreener
111.79
0.57%
0.63
Dopo l'orario di chiusura:
111.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5% - Simply Wall St
Gilead Prioritizes Women With Its First HIV Cure Trial In Africa - Clinical Leader
Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M - FiercePharma
Gilead to Boost China R&D to Make Access to Antiviral Drugs Faster, Country GM Says - Yicai Global
Gilead Sciences CEO's pay climbed to $23.7 million - The Business Journals
Gilead Says CEO Daniel O'Day's 2024 Total Compensation Was $23.7 MillionSEC Filing - Marketscreener.com
What Analysts Are Saying About Gilead Sciences Stock - Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics - Benzinga
J.P. Morgan Sticks to Their Buy Rating for Gilead Sciences (GILD) - The Globe and Mail
JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating - Marketscreener.com
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts - FiercePharma
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise. - Barron's
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer - CSRwire.com
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year? - Yahoo Finance
Gilead price tries to regain footingForecast today26-03-2025 - Economies.com
Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - StockTitan
Gilead, J&J Sue Laurus Labs to Block Copy of HIV Drug Complera - Bloomberg Law
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
The Inner Circle acknowledges, Christopher McCormick as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance
Gilead Sees Success With HIV PrEP Trial In South Africa - Clinical Leader
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval - Seeking Alpha
Gilead Sciences Inc (GILD) Shares Up 1.14% on Mar 22 - GuruFocus.com
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus.com
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
Gilead Sciences Inc (GILD) Stock Price Up 0.52% on Mar 21 - GuruFocus.com
Gilead Sciences stock performance analysis: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Nasdaq
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
GILD Stock Down on Report of Cut in HIV Prevention Spending - Yahoo Finance
Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts - Yahoo Finance
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed - MSN
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Yahoo Finance
Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal
Gilead stock falls on report of HIV prevention cuts - Yahoo Finance
Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Yahoo Finance
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada
BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com
Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com
Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com
Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research
Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barron's
Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks
Gilead slides as Trump administration puts HIV prevention funds under review - TradingView
Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets
1.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):